ArticlePublisher preview available
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

Background Research suggests that mindfulness-based interventions may improve mindfulness-related capacities (e.g., decentering, non-judging, and non-reacting) and emotion regulation. Previously, our group reported that ayahuasca could be a potential analogue of mindfulness practice. The main aim of the current study was to examine the effects of ayahuasca on emotional regulation and mindfulness-related capacities. Secondarily, we sought to explore the effects of ayahuasca on individuals with borderline personality disorder (BPD) traits. Method This is an observational study of 45 volunteers who participated in an ayahuasca session. The volunteers completed various self-report instruments designed to measure emotional dysregulation (Difficulties in Emotion Regulation Scale (DERS)) and mindfulness traits (Five Facet Mindfulness Questionnaire (FFMQ)–Short Form and Experiences Questionnaire (EQ)) prior to and 24 h after the ayahuasca session. The volunteers were divided into two subgroups based on their score on the McLean Screening Instrument for BPD (MSI-BPD). Twelve participants were grouped into the BPD-like traits subgroup while the rest of them were included in the non-BPD-like subgroup. We performed within-subjects and between-group analyses. Results Overall, the participants showed significant improvements on the FFMQ subscales observing, acting with awareness, non-judging, and non-reacting and also significantly improved on decentering (EQ scale) and on the DERS subscales emotional non-acceptance, emotional interference, and lack of control. The BPD-like subgroup also showed significant improvements on the DERS subscales emotional interference and lack of control but not in mindfulness capacities. Conclusions These findings suggest a potential therapeutic effect for ayahuasca in emotion regulation and mindfulness capacities (including decentering, acceptance, awareness, and sensitivity to meditation practice). Based on these results, we believe that ayahuasca therapy could be of value in clinical populations, such as individuals with BPD, affected by emotion dysregulation.
ORIGINAL INVESTIGATION
Ayahuasca improves emotion dysregulation in a community sample
and in individuals with borderline-like traits
Elisabet Domínguez-Cla
1,2,3
&Joaquim Soler
1,3,4
&Juan C. Pascual
1,3,4
&Matilde Elices
1,3
&Alba Franquesa
1
&
Marta Valle
2,3,5
&Enric Alvarez
1,4
&Jordi Riba
3,6,7
Received: 19 June 2018 / Accepted: 16 October 2018 / Published online: 7 November 2018
#Springer-Verlag GmbH Germany, part of Springer Nature 2018
Abstract
Background Research suggests that mindfulness-based interventions may improve mindfulness-related capacities (e.g.,
decentering, non-judging, and non-reacting) and emotion regulation. Previously, our group reported that ayahuasca could be a
potential analogue of mindfulness practice. The main aim of the current study was to examine the effects of ayahuasca on
emotional regulation and mindfulness-related capacities. Secondarily, we sought to explore the effects of ayahuasca on individ-
uals with borderline personality disorder (BPD) traits.
Method This is an observational study of 45 volunteers who participated in an ayahuasca session. The volunteers com-
pleted various self-report instruments designed to measure emotional dysregulation (Difficulties in Emotion Regulation
Scale (DERS)) and mindfulness traits (Five Facet Mindfulness Questionnaire (FFMQ)Short Form and Experiences
Questionnaire (EQ)) prior to and 24 h after the ayahuasca session. The volunteers were divided into two subgroups based
on their score on the McLean Screening Instrument for BPD (MSI-BPD). Twelve participants were grouped into the BPD-
like traits subgroup while the rest of them were included in the non-BPD-like subgroup. We performed within-subjects and
between-group analyses.
Results Overall, the participants showed significant improvements on the FFMQ subscales observing,acting with
awareness,non-judging,andnon-reacting and also significantly improved on decentering (EQ scale) and on the DERS
subscales emotional non-acceptance,emotional interference,andlack of control. The BPD-like subgroup also showed
significant improvements on the DERS subscales emotional interference and lack of control but not in mindfulness
capacities.
Conclusions These findings suggest a potential therapeutic effect for ayahuasca in emotion regulation and mindfulness
capacities (including decentering, acceptance, awareness, and sensitivity to meditation practice). Based on these results,
we believe that ayahuasca therapy could be of value in clinical populations, such as individuals with BPD, affected by
emotion dysregulation.
Keywords Ayahu asca .Emotional dysregulation .Mindfulness .Borderline personality disorder
*Joaquim Soler
jsolerri@santpau.cat
*Jordi Riba
jordi.riba@maastrichtuniversity.nl
1
Servei de Psiquiatria, Hospital dela Santa Creu i Sant PauInstitut de
Recerca, Barcelona, Spain
2
Department of Pharmacology and Therapeutics, Universitat
Autònoma de Barcelona (UAB), Barcelona, Spain
3
Centro de Investigación Biomédica en Red de Salud Mental,
CIBERSAM, Barcelona, Spain
Psychopharmacology (2019) 236:573580
https://doi.org/10.1007/s00213-018-5085-3
4
Departament de Psiquiatria i Medicina Legal, Universitat Autònoma
de Barcelona, Barcelona, Spain
5
Pharmacokinetic and Pharmacodynamic Modelling and Simulation,
Sant Pau Institute of Biomedical Research (IIB-Sant Pau),
Barcelona, Spain
6
Human Neuropsychopharmacology Group, Sant Pau Institute of
Biomedical Research (IIB-Sant Pau), Barcelona, Spain
7
Present address: Department of Neuropsychology and
Psychopharmacology, Masstricht University,
Maastricht, The Netherlands
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
... Notably, the patient did not rate positive for the diagnoses of paranoid and narcissistic PD after one year of treatment (despite still rating positive for borderline and antisocial PDs), and important improvements were found in borderline, narcissistic, and obsessive-compulsive symptomatology. These improvements recall past studies on the effects of psychedelics in borderline patients (Domínguez-Clavé et al., 2019) and on pathological narcissism (van Mulukom et al., 2020), and can be linked with the improvements we found in alexithymia, emotion regulation, and social functioning. Indeed, these three dimensions are core aspects that are targeted in PD-tailored treatments (namely, mentalization-based therapy (Bateman & Fonagy, 2010), dialectical-behavioral therapy (Linehan, 1993) and good psychiatric management (Gunderson, 2014)) and their improvement is thought to be at the core of PD improvement. ...
... We also tested whether trait mindfulness mediated group differences in death processing. Cross sectional studies have associated psychedelic use to higher trait mindfulness (Sampedro et al., 2017), and a number of studies have reported increases in mindfulness following psychedelic interventions (Madsen et al., 2020;Søndergaard et al., 2022;Uthaug et al., 2019), and ayahuasca usage in particular (Domínguez-Clavé et al., 2019;Murphy-Beiner and Soar, 2020;Sampedro et al., 2017;Soler et al., 2016Soler et al., , 2018Uthaug et al., 2018). More generally, mindfulness meditation training has been shown to decrease explicit fear of death and dying (Anālayo et al., 2022), as well as unconscious thought suppression and defensiveness (Park and Pyszczynski, 2019). ...
Preprint
Full-text available
Background: How the human psyche interacts with the theme of death is fundamental to individual and societal life, profoundly influencing cognition, affect, and behavior. Death-related psychological phenomena, such as death anxiety and acceptance, have been shown in clinical studies to be influenced by psychedelic (LSD and psilocybin) interventions. However, the literature lacks a comprehensive assessment of death-related processes in non-clinical settings, the mechanisms underlying long-term changes, and in particular, the effects of ayahuasca—a potent Amazonian psychedelic brew—on these dimensions.Methods: The present cross-sectional study addresses these issues by comprehensively investigating death processing, candidate mechanisms-of-change, and their predictors, in ayahuasca veterans (N=54) compared to non-users (N=53). For this purpose, a battery of questionnaires and behavioral measures targeting various aspects of death processing were employed. These included fear and anxiety of death, death acceptance, death-avoidant behaviors, and accessibility of death thoughts. Tested mediators included personality, ontological afterlife beliefs, trait mindfulness and the construct of impermanence awareness and acceptance. Results: The findings demonstrated lower levels of death anxiety, avoidant behavior and explicit and implicit fear-of-death, as well as greater acceptance of death, for ayahuasca veterans. Mediation analyses revealed that these group differences were not due to demographics, personality, trait mindfulness, ontological beliefs, or impermanence awareness, but rather to impermanence acceptance. Finally, within the ayahuasca group, lifetime ego dissolution experiences, but not ayahuasca intake habits, predicted degree of impermanence acceptance. Conclusions: These findings demonstrate robust and multi-dimensional differences in how death is processed by ayahuasca veterans relative to non-psychedelic users. In contrast to literature suggestions, degree of impermanence acceptance but not ontological beliefs are shown to be the underlying mechanisms-of-change. Finally, the findings support the role of acute subjective ayahuasca experiences in inducing long-term effects. Future (psychedelic and non-psychedelic) interventions can directly target impermanence acceptance for effectively managing existential terror.
... A study by Domínguez-Clavé et al. [154] revealed that ayahuasca increases emotion regulation and mindfulness abilities in the 24-hour period after the intake, especially in individuals with borderline-like traits, who suffer significantly with emotional dysregulation. In addition, there is evidence [155] that ayahuasca helps to improve self-compassion and self-criticism capacities in the 24-hour period after the intake, which could have therapeutic implications on emotional regulation. ...
Article
Full-text available
Purpose of Review Self-awareness can be defined as the capacity of becoming the object of one’s own awareness and, increasingly, it has been the target of scientific inquiry. Self-awareness has important clinical implications, and a better understanding of the neurochemical basis of self-awareness may help clarifying causes and developing interventions for different psychopathological conditions. The current article explores the relationship between neurochemistry and self-awareness, with special attention to the effects of psychedelics. Recent Findings The functioning of self-related networks, such as the default-mode network and the salience network, and how these are influenced by different neurotransmitters is discussed. The impact of psychedelics on self-awareness is reviewed in relation to specific processes, such as interoception, body ownership, agency, metacognition, emotional regulation and autobiographical memory, within a framework based on predictive coding. Summary Improved outcomes in emotional regulation and autobiographical memory have been observed in association with the use of psychedelics, suggesting higher-order self-awareness changes, which can be modulated by relaxation of priors and improved coping mechanisms linked to cognitive flexibility. Alterations in bodily self-awareness are less consistent, being potentially impacted by doses employed, differences in acute/long-term effects and the presence of clinical conditions. Future studies investigating the effects of different molecules in rebalancing connectivity between resting-state networks may lead to novel therapeutic approaches and the refinement of existing treatments.
... Notably, a recent case report described signi cant reductions in depressed mood, emotional instability, and suicidal ideation following psychedelic treatment in a patient with mixed PD. (47,48) Recent research by Marrocu et al. also found transient improvements in psychological well-being 2-weeks following naturalistic psychedelic use among individuals with a PD diagnosis.(49) However, no recent prospective cohort studies have examined the effect of psychedelic use on affective symptoms (e.g., depressive symptoms or anxiety) or psychological mechanisms (e.g., emotion regulation, cognitive exibility) for individuals with a PD diagnosis. ...
Preprint
Full-text available
Background: Personality disorders (PDs) are characterized by impairments in psychological functioning for which pharmacologic treatments have demonstrated limited efficacy. Psychedelics may offer a potential PD treatment, given support for their potential enduring positive effects on psychological functioning. However, little is known about the safety or therapeutic effects of psychedelics among individuals with a PD. Therefore, we examined the effects of psychedelic use on mental health among individuals with a PD. Methods: Study 1 included three prospective observational studies where 21 individuals with a PD diagnosis completed mental health measures (depressive symptoms, anxiety, and suicidal ideation [SI]) before, 2 weeks (except SI), and 4 weeks after psychedelic use. Study 2 was a prospective observational study in which 55 individuals with a PD diagnosis completed mental health measures (anxiety, depressive symptoms, cognitive flexibility, expressive suppression, and cognitive reappraisal) before, 2-4 weeks, and 2-3 months after psychedelic use. Results: In Study 1, elevations in SI were rare (6.67%) with no elevations to high risk of suicidal behavior post-psychedelic use. All participants with high baseline risk of suicidal behavior (6.67%) were at low-risk post-psychedelic use. SI reduced at 4 weeks (Hedges’ g=0.52). There were several cases of increased anxiety (Study 1: 13.6%-25.0%; Study 2: 16.3%-11.5%) and clinically significant worsening of depression symptoms (Study 1: 14.3%-14.2%; Study 2: 10.0%-8.0%). Across both studies, psychedelic use was associated with reductions in anxiety (Study 1: g=-.46–-.57; Study 2 g=-.52–-.89) and depression (Study 1 g=-.54–-0.59; Study 2 rs= .52–.57) . In Study 2, there were transient increases in cognitive flexibility at 2-4 weeks (g=.26) and sustained increases in cognitive reappraisal up to 2-3 months (g=.36). Increases in cognitive reappraisal were associated with reductions in anxiety (r=.33) and depression (rs=.37). Conclusion: For individuals with PD, psychedelic use was associated with improvements in psychological functioning. There were no clinically significant elevations in SI and several cases of elevations in anxiety and depression severity. The studies are limited by a small sample size, self-reported data, and lack of differentiation between PDs. Further research should explore the safety and potential therapeutic effects of psychedelics among individuals with PD.
... On the other hand, Ayahuasca, a spiritual ritual [96]-also known as the tea, the vine, and la purga-a brew made from the leaves of the Psychotria viridis shrub along with the stalks of the Banisteriopsis caapi vine, as reported by Savoldi et al. [97], is linked with better emotion control [98], a long-time reduction in depression and stress [99], and the potential to cure drug addiction [100]. A spiritual reconnection of the self to body, nature and society, and eating disorders is strongly discussed, but is it not a spiritual reconnection to God? ...
Article
Full-text available
Food production is a complex matter, affecting people's lives, organizations' profits, and the well-being of the whole planet, and has multifaceted ethical considerations surrounding its production, distribution, and consumption. This paper addresses the pressing need to confront ethical challenges within the food system, encompassing issues such as environmental sustainability, food security, and individual food choices for better oral and systemic health of all individuals around the globe. From agricultural practices to global trade and food waste, ethical implications are addressed across various domains, highlighting the interconnectedness of ethical decision-making in the food industry. Central themes explored include the ethical dimensions of food production methods, the impact of global trade on food ethics, and the role of individuals in making ethically informed food choices. Additionally, this paper considers the spiritual and physical significance of food, particularly through the lens of oral health as a gateway to holistic well-being. Recognizing the complexity of the food and mouth ecosystem, this paper calls for serious interventions in legislation and economics to promote ethical protocols and techniques for sustainability reasons. It emphasizes the importance of ethical considerations in food safety management systems, regulatory frameworks, and quality standards. Moreover, this paper underlines the need for a comprehensive approach to address ethical dilemmas and moral values inherent in the food industry and oral health policies, adopting the precautionary principle and ethical decision-making frameworks. This article finally aims to serve as a call to action for stakeholders across the food industry and the healthcare sector, to prioritize ethical practices, promote transparency, rearrange economic parameters, and work towards a more sustainable and equitable food system for inner and outer oral and systemic health and human sustainability for all.
... Furthermore, within this trial, increases in experiential acceptance following psilocybin-assisted therapy predicted improvements in depression severity, anxiety, suicidal ideation, and well-being 41 . Within non-clinical samples, several studies have observed increases in facets of mindfulness (most consistently the facets of experiential acceptance/non-judgmental awareness) following use/administration of classic psychedelics 22,[42][43][44][45][46][47][48][49] , including psilocybin 50-52 (for a review, see 53 ). Furthermore, in observational studies, increases in non-judgment of inner experience (closely related to experiential acceptance) following psilocybin were associated with reductions in anxiety 50 . ...
Article
Full-text available
Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests that improvements in psychological flexibility may mediate therapeutic effects. However, no psychedelic trials to date have substantiated this finding in a clinical sample. In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with moderate to severe MDD were administered placebo (n = 19) followed by psilocybin (0.3 mg/kg) (n = 15) 4 weeks later. Dosing sessions were embedded within a manualized psychotherapy that incorporated principles of Acceptance and Commitment Therapy. Depression severity, psychological flexibility, mindfulness, and values-congruent living were measured over a 16-weeks study period. Psychological flexibility, several facets of mindfulness, and values-congruent living significantly improved following psilocybin and were maintained through week 16. Additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin. These findings support the theoretical premise of integrating psilocybin treatment with psychotherapeutic platforms that target psychological flexibility and add to emerging evidence that increasing psychological flexibility may be an important putative mechanism of change in psilocybin-assisted therapy for MDD and potentially, other mental health conditions.
Article
Full-text available
The psychoactive decoction Ayahuasca (AYA) used for therapeutic and religious purposes by indigenous groups and peoples from Amazonian regions produces anti-inflammatory and neuroprotective effects. Thus, it may be useful to attenuate the neuroinflammation and related anxiety- and depressive-like symptoms elicited by inflammatory insults such as sepsis. Rats were pretreated for 3 days with different doses of AYA. Twenty-four hours after, cecal ligation and puncture (CLP) was performed. On days 1–4, post-CLP behavioral tests to assess anxiety-like behavior were performed. After 24-h, neuroinflammation, oxidative stress, myeloperoxidase activity, and mitochondrial metabolism were assessed in the prefrontal cortex (PFC), hippocampus (HP), and cortex. AYA pretreatment increased the time spent in the open arms of the elevated plus maze and prevented the sepsis-induced hyper-grooming and -rearing behavior, suggesting an anxiolytic effect. AYA pretreatment increased the levels of the anti-inflammatory interleukin 4, in the PFC and the cortex, and brain-derived neurotrophic factor in the cortex. Moreover, AYA pretreatment increased myeloperoxidase activity in the PFC and the HP and decreased nitrite/nitrate concentration in the PFC, HP, and cortex of septic rats, suggesting enhanced neutrophil activation and decreased nitric oxide signaling. Furthermore, AYA pretreatment prevented lipid peroxidation in the PFC, HP, and cortex of septic rats as measured by decreased levels of thiobarbituric acid reactive substances. Levels of protein carbonyls and activity of superoxide dismutase, citrate synthase, succinate dehydrogenase, and mitochondrial respiratory chain were not affected. Together, AYA represents a promising approach to prevent sepsis-induced neuroinflammatory and oxidative stress and associated anxiety-like symptoms.
Article
Full-text available
CITATION Chaves C, dos Santos RG, Dursun SM, Tusconi M, Carta MG, Brietzke E and Hallak JEC (2024) Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
Preprint
Full-text available
Background: Personality disorders (PDs) are characterized by impairments in psychological functioning for which pharmacologic treatments have demonstrated limited efficacy. Psychedelics may offer a possible PD treatment, given preliminary evidence for their potential long-term positive effects on psychological functioning. However, little is known about safety or potential therapeutic effects of psychedelics among individuals with a PD. Therefore, we examined the effects of psychedelic use on mental health among individuals who reported a PD diagnosis. Methods: Study 1 included three prospective observational studies where 21 individuals who reported a PD diagnosis completed mental health measures (depression symptoms, anxiety, and suicidal ideation [SI]) before, 2 weeks, and 4 weeks after psychedelic use. Study 2 was a prospective observational study where 55 individuals who reported a PD diagnosis completed mental health measures (anxiety, depressive symptoms, cognitive flexibility, expressive suppression, and cognitive reappraisal) before, 2-4 weeks, and 2-3 months after psychedelic use. Results: In Study 1, all participants with high baseline risk of suicidal behavior (6.67%) became low-risk post-psychedelic use. Post-psychedelic increases in SI were rare (6.67%) with no increases to high risk of suicidal behavior. SI reduced at 4 weeks (Hedges’ g=0.52). There were few cases of clinically significant worsening anxiety (Study 1:0.0%; Study 2:7.7%-8.2%) and depression symptoms (Study 1:0.0%-7.1%; Study 2:0.0%). However, across both studies, psychedelic use was associated with reductions in anxiety (Study 1:g=-0.46–-0.57; Study 2:g=-0.52–-0.89) and depression (Study 1 g=-0.54–-0.59; Study 2 rs=.52–.57). In Study 2, there were transient increases in cognitive flexibility at 2-4 weeks (g=0.26) and sustained increases in cognitive reappraisal up to 2-3 months (g=0.36). Increases in cognitive reappraisal were associated with reductions in anxiety (r=-.33) and depression (rs=-.37). Conclusion: For individuals who reported a PD diagnosis, psychedelic use was associated with improvements in mental health outcomes. There were no clinically significant post-psychedelic increases in SI but there were a few cases of clinically significant increases in anxiety and depression severity. The studies are limited by a small sample size, self-reported data, and lack of differentiation between PDs. Further research is needed to explore the safety and potential therapeutic effects of psychedelics among individuals with PD.
Article
Full-text available
Background: The therapeutic effects of the Amazonian plant tea ayahuasca may relate to its ability to enhance mindfulness capacities. Ayahuasca induces a modified state of awareness through the combined action of its active principles: the psychedelic N,N-dimethyltryptamine (DMT) and a series of centrally acting β-carbolines, mainly harmine and tetrahydroharmine. To better understand the therapeutic potential of ayahuasca, here we compared the impact on mindfulness capacities induced by two independent interventions: (a) participation in four ayahuasca sessions without any specific purpose related to improving mindfulness capacities; and (b) participation in a standard mindfulness training course: 8 weeks mindfulness-based stress reduction (MBSR), with the specific goal of improving these skills. Methods: Participants of two independent groups completed two self-report instruments: The Five Facet Mindfulness Questionnaire (FFMQ) and the Experiences Questionnaire (EQ). The MINDSENS Composite Index was also calculated, including those EQ and FFMQ items that have proven to be the most sensitive to meditation practice. Group A (n = 10) was assessed before and after the last of four closely spaced consecutive ayahuasca sessions. Group B (n = 10) was assessed before and after completion of a standard 8-week MBSR course. Results: MBSR training led to greater increases in overall mindfulness scores after the 8-week period. MBSR but not ayahuasca led to increases in the MINDSENS Composite Index. However, the ayahuasca sessions induced comparable increases in the Non-Judging subscale of the FFMQ, specifically measuring “acceptance.” Improving this capacity allows for a more detached and less judgmental stance toward potentially distressing thoughts and emotions. Results: The present findings suggest that a small number of ayahuasca sessions can be as effective at improving acceptance as more lengthy and costly interventions. Future studies should address the benefits of combining ayahuasca administration with mindfulness-based interventions. This will allow us to investigate if ayahuasca will improve the outcome of psychotherapeutic interventions.
Article
Full-text available
Background: Ayahuasca is a plant tea containing the psychedelic 5-HT2A agonist N,N-dimethyltryptamine (DMT) and harmala monoamine-oxidase inhibitors. Acute administration leads to neurophysiological modifications in brain regions of the default mode network (DMN), purportedly through a glutamatergic mechanism. Post-acutely, ayahuasca potentiates mindfulness capacities in volunteers, and induces rapid and sustained antidepressant effects in treatment-resistant patients. However, the mechanisms underlying these fast and maintained effects are poorly understood. Here we investigated in an open-label uncontrolled study in sixteen healthy volunteers ayahuasca-induced post-acute neurometabolic and connectivity modifications, and their association with mindfulness measures. Methods: Using 1H-magnetic resonance spectroscopy (MRS) and functional connectivity, we compared baseline and post-acute neurometabolites and seed-to-voxel connectivity in the posterior (PCC) and anterior (ACC) cingulate cortex after a single ayahuasca dose. Results: MRS showed post-acute reductions in Glx (glutamate+glutamine), creatine and NAA-NAAG (N-acetylaspartate+N-acetylaspartylglutamate) in the PCC. Connectivity was increased between the PCC and the ACC, and between the ACC and limbic structures in the right medial temporal lobe (MTL). Glx reductions correlated with increases in the "Non-Judging" subscale of the Five Facets Mindfulness Questionnaire. Increased ACC-MTL connectivity correlated with increased scores on the Self-Compassion questionnaire. Post-acute neural changes predicted sustained elevations in "Non-Judging" two months later. Conclusions: These results support the involvement of glutamate neurotransmission in the effects of psychedelics in humans. They further suggest that neurometabolic changes in the PCC, a key region within the DMN, and increased connectivity between the ACC and MTL structures involved in emotion and memory, potentially underlie the post-acute psychological effects of ayahuasca.
Article
Full-text available
Introduction: This paper reports results from a preliminary observational study of ayahuasca-assisted treatment for problematic substance use and stress delivered in a rural First Nations community in British Columbia, Canada. Methods: The "Working with Addiction and Stress" retreats combined four days of group counselling with two expert-led ayahuasca ceremonies. This study collected pre-treatment and six months follow-up data from 12 participants on several psychological and behavioral factors related to problematic substance use, and qualitative data assessing the personal experiences of the participants six months after the retreat. Findings: Statistically significant (p < 0.05) improvements were demonstrated for scales assessing hopefulness, empowerment, mindfulness, and quality of life meaning and outlook subscales. Self-reported alcohol, tobacco and cocaine use declined, although cannabis and opiate use did not; reported reductions in problematic cocaine use were statistically significant. All study participants reported positive and lasting changes from participating in the retreats. Conclusions: This form of ayahuasca-assisted therapy appears to be associated with statistically significant improvements in several factors related to problematic substance use among a rural aboriginal population. These findings suggest participants may have experienced positive psychological and behavioral changes in response to this therapeutic approach, and that more rigorous research of ayahuasca-assisted therapy for problematic substance use is warranted.
Article
Full-text available
“Distress disorders,” which include generalized anxiety disorder and major depression are often highly comorbid with each other and appear to be characterized by common temperamental features that reflect heightened sensitivity to underlying motivational systems related to threat/safety and reward/loss. Further, individuals with distress disorders tend to utilize self-referential processes (e.g., worry, rumination, self-criticism) in a maladaptive attempt to respond to motivationally relevant distress, often resulting in suboptimal contextual learning. Despite the success of cognitive behavioral therapies for emotional disorders, a sizable subgroup of patients with distress disorders fail to evidence adequate treatment response. Emotion Regulation Therapy (ERT) is a theoretically derived, evidence based, treatment that integrates principles (e.g., skills training, exposure) from traditional and contemporary therapies with findings from basic and translational affective science to offer a framework for improving intervention by focusing on the motivational responses and corresponding regulatory characteristics of individuals with high levels of chronic distress. Open and randomized controlled trials have demonstrated preliminary support for the utility of ERT as reflected by strong effect sizes comparable to and exceeding established intervention approaches. In addition, pilot findings support the role of underlying proposed mechanisms in this efficacious response. This article presents the functional model associated with ERT and describes the proposed mechanisms of the treatment. Additionally, a clinical case is presented, allowing the reader to gain a greater applied understanding of the different components of the ERT model and treatment.
Article
Given recent attention to emotion regulation as a potentially unifying function of diverse symptom presentations, there is a need for comprehensive measures that adequately assess difficulties in emotion regulation among adults. This paper (a) proposes an integrative conceptualization of emotion regulation as involving not just the modulation of emotional arousal, but also the awareness, understanding, and acceptance of emotions, and the ability to act in desired ways regardless of emotional state; and (b) begins to explore the factor structure and psychometric properties of a new measure, the Difficulties in Emotion Regulation Scale (DERS). Two samples of undergraduate students completed questionnaire packets. Preliminary findings suggest that the DERS has high internal consistency, good test–retest reliability, and adequate construct and predictive validity.
Article
Ayahuasca is a psychedelic decoction originating from Amazonia. The ayahuasca-induced introspective experience has been shown to have potential benefits in the treatment of several pathologies, to protect mental health and to improve neuropsychological functions and creativity, and boost mindfulness. The underlying psychological processes related to the use of ayahuasca in a psychotherapeutic context are not yet well described in the scientific literature, but there is some evidence to suggest that psychological variables described in psychotherapies could be useful in explaining the therapeutic effects of the brew. In this study we explore the link between ayahuasca use and Decentering, Values and Self, comparing subjects without experience of ayahuasca (n = 41) with subjects with experience (n = 81). Results confirm that ayahuasca users scored higher than non-users in Decentering and Positive self, but not in Valued living, Life fulfillment, Self in social relations, Self in close relations and General self. Scores in Decentering were higher in the more experienced subjects (more than 15 occasions) than in those with less experience (less than 15 occasions). Our results show that psychological process variables may explain the outcomes in ayahuasca psychotherapy. The introduction of these variables is warranted in future ayahuasca therapeutic studies.
Article
Non-suicidal self-injury (NSSI) is highly prevalent during late adolescence and young adulthood. There is some evidence of a link between NSSI and Borderline Personality Disorder (BPD), but little is known about the association between BPD traits and the various functions that maintain NSSI. The main purpose of this study was to explore the association between borderline personality traits and NSSI functions in a sample of college students. We also compared NSSI functions in college students who engaged in NSSI to those in an age-matched sample of BPD patients. This study included a total of 238 college students and 36 BPD patients. Participants were asked to complete a number of clinical measures. In the non-clinical sample, BPD features were more pronounced in the presence of NSSI, and we observed a differential relationship between NSSI functions and psychopathological BPD-traits. The NSSI clinical variables most strongly associated with BPD were frequency, variety of methods and severity, but not age of onset. Our results provide new information on the relationship between BPD and NSSI in young adults, and could be used to improve the early detection of vulnerable BPD-individuals and in planning NSSI treatment.
Article
Objective: To describe the pharmacological management of borderline personality disorder (BPD) in Spain from 2001 through 2016, the factors associated with prescriptions, and changes in pharmacotherapy over this time period. Methods: Retrospective, cross-sectional, observational study conducted in a sample of 457 patients with BPD consecutively admitted to a specialist BPD Program between January 2001 and November 2016. Data on sociodemographic and clinical variables, as well as pharmacological treatment upon the admission to the programme, were used to describe pharmacological prescriptions, the factors associated with these medications, and changes in prescription over the last 15 years. Results: Most (88.4%) patients were on pharmacological treatment, with 53.8% of persons taking ≥3 medications. No significant changes in these percentages were observed over the study period. The use of tricyclic antidepressants and benzodiazepines decreased, while the use of atypical antipsychotics increased. Axis I comorbidity was the main factor associated with pharmacological treatment and polypharmacy. Conclusions: This study provides further evidence confirming the worldwide overuse of prescription medications for BPD and shows that there has been a shift in the prescription pattern in the last 15 years. These results suggest that real clinical practice only partially adheres to clinical treatment guidelines.